Hyppää sisältöön
    • Suomeksi
    • In English
Trepo
  • Suomeksi
  • In English
  • Kirjaudu
Näytä viite 
  •   Trepo etusivu
  • Trepo
  • Artikkelit
  • Näytä viite
  •   Trepo etusivu
  • Trepo
  • Artikkelit
  • Näytä viite
JavaScript is disabled for your browser. Some features of this site may not work without it.

The effect of co-morbidities on health-related quality of life in patients placed on the waiting list for total joint replacement

Tuominen, Ulla; Blom, Marja; Hirvonen, Johanna; Seitsalo, Seppo; Lehto, Matti; Paavolainen, Pekka; Hietaniemi, Kalevi; Rissanen, Pekka; Sintonen, Harri (2007)

 
Tweet refworks
 
Avaa tiedosto
the_effect_of_co-morbidities_2007.pdf (267.0Kt)
Lataukset: 



Tuominen, Ulla
Blom, Marja
Hirvonen, Johanna
Seitsalo, Seppo
Lehto, Matti
Paavolainen, Pekka
Hietaniemi, Kalevi
Rissanen, Pekka
Sintonen, Harri
2007

Health and Quality of Life Outcomes 5
16
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited.
doi:10.1186/1477-7525-5-16
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
http://urn.fi/urn:nbn:uta-3-610

Kuvaus

BioMed Central Open access
Tiivistelmä
Background

Co-morbidity is a powerful predictor of health care outcomes and costs, as well as an important cofounder in epidemiologic studies. The effect of co-morbidities is generally related to mortality or complications. This study evaluated the association between co-morbidity and health-related quality of life (HRQoL) in patients awaiting total joint replacement.

Methods

A total of 893 patients were recruited to the study between August 2002 and November 2003 in four Finnish hospitals. The effect of co-morbidity on HRQoL was measured by the generic 15D instrument and by a Visual Analog Scale (VAS). Comparative variance analysis of socio-demographic and clinical characteristics was described by using either an independent samples t-test or the Chi-square test. The differences in each of the 15D dimensions and the overall 15D single index score for patients were calculated. Two-sided p-values were calculated with the Levene Test for Equality of Variances.

Results

Patients with co-morbidity totaled 649; the incidence of co-morbidity was 73%. The mean number of co-morbidities among the patients was two. At baseline the 15D score in patients with and without co-morbidity was 0.778 vs 0.816, respectively. The difference of the score (0.038) was clinically and statistically significant (P < 0.001). The patients' scores with and without co-morbidity on the different 15D dimensions related to osteoarthritis-moving, sleeping, usual activities, discomfort and symptoms, vitality and sexual activity–were low in both groups. Patients with co-morbidity scored lower on the dimensions of moving, vitality and sexual activity compared to the patients without co-morbidity. Co-morbidity was significantly associated with a reduced HRQoL. Patients without co-morbidity had poorer VAS, arthritis had strong effect to their quality of life compared to the patients with co-morbidity.

Conclusion

Assessing co-morbidity in patients placed on the waiting list for joint replacement may be useful method to prioritization in medical decision-making for healthcare delivery. The assessment of co-morbidities during waiting time is important as well as evaluating how the co-morbidity may affect the final outcomes of the total joint replacement.
Kokoelmat
  • Artikkelit [6066]
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Yhteydenotto | Tietosuoja | Saavutettavuusseloste
 

 

Selaa kokoelmaa

TekijätNimekkeetTiedekunta (2019 -)Tiedekunta (- 2018)Tutkinto-ohjelmat ja opintosuunnatAvainsanatJulkaisuajatKokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Yhteydenotto | Tietosuoja | Saavutettavuusseloste